Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New European Vaccine Initiative

Published: Tuesday, November 26, 2013
Last Updated: Tuesday, November 26, 2013
Bookmark and Share
Leading organisations have joined forces to rapidly assess and communicate the benefits and risks of vaccines.

ADVANCE, as the project is called, is in collaboration between European researchers, public health, regulatory agencies and vaccine manufacturers. Karolinska Institutet coordinates the Swedish participation in the project.

The initiative aims to help government agencies and decision-makers in the healthcare field to make quick and well-informed decisions regarding strategies for vaccinating the European population. Such a framework would make it easier for regulators and public health authorities to make fast, more informed decisions regarding vaccination strategies, and help to maintain public confidence in immunisation, particularly when questions are raised about the safety of specific vaccines.

Researchers at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet will participate in the scientific studies that are planned within the ADVANCE project and also contribute their expertise regarding the establishment of the framework. Other Swedish participants include the Swedish Institute for Communicable Disease Control (SMI) and the European Centre for Disease Prevention and Control (ECDC), which has its headquarters in Sweden. Other important partners include the European equivalent of the Swedish Medical Products Agency, EMA, Erasmus University Rotterdam, and several major pharmaceutical companies.

The initiative is funded by the Innovative Medicines Initiative (IMI), which in turn is a collaboration between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA). ADVANCE (Accelerated Development of Vaccine Benefit-risk Collaboration in Europe) receives the equivalent of SEK 95 million in funding over five years. Karolinska Institutet will receive SEK 1.4 million over the same period.

"This collaboration is unique as it is the first time that a European framework is created for evaluating vaccines. It is important that we participate in this project as Sweden has excellent prerequisites, through our health care data register, for evaluating vaccines on a population-based level", says Lisen Arnheim Dahlström, project investigator from Karolinska Institutet.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Possible Goal for New Tuberculosis-Vaccine Identified
A new study shows for the first time the essential role of the molecule SOCS3 in the control of Tuberculosis.
Monday, July 08, 2013
New Hope for Setback-dogged Cancer Treatment
Researchers at Karolinska Institutet announce breakthrough in the study of how IGF-1 receptor-binding antibodies can help those with cancer.
Wednesday, November 28, 2012
Possible New Therapy for the Treatment of a Common Blood Cancer
Research from Karolinska Institutet shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma.
Friday, September 07, 2012
Scientific News
Madison Researchers Begin Work on Zika Virus
Work will start with basic questions about Zika virus infection.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!